XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.1
REVENUES (Tables)
 3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
Contract with Customer, Contract Asset The following table summarizes our contract assets:
(in millions)March 31,
2023		December 31,
2022
Contract manufacturing services$49 $51 
Software sales42 43 
Bundled equipment and consumable medical products contracts120 121 
Contract assets$211 $215 
The following table summarizes contract liability activity for the three months ended March 31, 2023 and 2022. The contract liability balance represents the transaction price allocated to the remaining performance obligations.
Three Months Ended March 31,
(in millions)
2023
2022
Balance at beginning of period$244 $246 
New revenue deferrals113 116 
Revenue recognized upon satisfaction of performance obligations(121)(122)
Currency translation1 — 
Balance at end of period$237 $240 
For the three months ended March 31, 2023 and 2022, $68 million and $50 million of revenue was recognized that was included in contract liabilities as of December 31, 2022 and 2021, respectively.
The following table summarizes the classification of contract assets and contract liabilities as reported in the condensed consolidated balance sheets:
(in millions)March 31,
2023		December 31,
2022
Prepaid expenses and other current assets$92 $93 
Other non-current assets119 122 
Contract assets$211 $215 
Accrued expenses and other current liabilities$160 $164 
Other non-current liabilities77 80 
Contract liabilities$237 $244 
Net Sales from Contracts with Customers by Global Business Unit
The following tables disaggregate our net sales from contracts with customers by product category between the U.S. and international:
Three Months Ended March 31,
20232022
(in millions)U.S.InternationalTotalU.S.InternationalTotal
Renal Care 1
$232 $660 $892 $225 $669 $894 
Medication Delivery 2
436 251 687 472 234 706 
Pharmaceuticals 3
173 350 523 157 364 521 
Clinical Nutrition 4
78 146 224 84 143 227 
Advanced Surgery 5
144 102 246 136 92 228 
Acute Therapies 6
61 119 180 68 120 188 
BioPharma Solutions 7
69 70 139 52 104 156 
Patient Support Systems 8
260 88 348 295 88 383 
Front Line Care 9
221 81 302 207 87 294 
Global Surgical Solutions 10
38 43 81 37 41 78 
Other 11
22 5 27 24 8 32 
Total Baxter$1,734 $1,915 $3,649 $1,757 $1,950 $3,707 
1Renal Care includes sales of our peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services.
2Medication Delivery includes sales of our intravenous (IV) therapies, infusion pumps, administration sets and drug reconstitution devices.
3Pharmaceuticals includes sales of our premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services.
4Clinical Nutrition includes sales of our parenteral nutrition therapies and related products.
5Advanced Surgery includes sales of our biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention.
6Acute Therapies includes sales of our continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU).
7BioPharma Solutions includes sales of contracted services we provide to various pharmaceutical and biopharmaceutical companies.
8Patient Support Systems includes sales of our connected care solutions: devices, software, communications and integration technologies and smart beds.
9Front Line Care includes sales of our integrated patient monitoring and diagnostic technologies to help diagnose, treat and manage a wide variety of illness and diseases, including respiratory therapy, cardiology, vision screening and physical assessment.
10Global Surgical Solutions includes sales of our surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories.
11Other includes sales of miscellaneous product and service offerings.
Sales-type Lease, Lease Income The components of lease revenue for the three months ended March 31, 2023 and 2022 were:
(in millions)Three months ended March 31, 2023Three months ended March 31, 2022
Sales-type lease revenue$4 $3 
Operating lease revenue124 122 
Variable lease revenue15 20 
Total lease revenue$143 $145 
Operating Lease, Lease Income The components of lease revenue for the three months ended March 31, 2023 and 2022 were:
(in millions)Three months ended March 31, 2023Three months ended March 31, 2022
Sales-type lease revenue$4 $3 
Operating lease revenue124 122 
Variable lease revenue15 20 
Total lease revenue$143 $145